dengue fever pipeline insight

DelveInsight’s, “Dengue Fever - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Dengue Fever: Understanding

Dengue Fever: Overview

Dengue fever is a mosquito-borne viral infection caused by the dengue virus, which is transmitted primarily by Aedes aegypti mosquitoes. It is prevalent in tropical and subtropical regions around the world, especially in Southeast Asia, the Pacific Islands, the Caribbean, and Central and South America. The disease presents with a sudden onset of high fever, severe headache, pain behind the eyes, joint and muscle pain, rash, and mild bleeding manifestations such as nose or gum bleeding, or easy bruising. Symptoms typically appear 4–10 days after the mosquito bite and can last for 2–7 days.

 

The clinical course of dengue fever can vary from mild to severe. Severe cases, known as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), involve severe abdominal pain, persistent vomiting, rapid breathing, bleeding gums, fatigue, restlessness, and blood in vomit or stool. These severe forms can lead to circulatory system failure, shock, and death if not managed promptly and appropriately. Children and individuals with a second dengue infection are at higher risk of developing severe dengue.

 

There is no specific antiviral treatment for dengue fever; management focuses on supportive care to alleviate symptoms and maintain fluid balance. Prevention is key and includes measures to reduce mosquito exposure, such as using insect repellent, wearing long-sleeved clothing, and eliminating standing water where mosquitoes breed. Vaccination efforts are ongoing, and one vaccine, Dengvaxia, has been approved for use in certain endemic areas, though it is recommended only for individuals with a previous dengue infection due to the risk of severe dengue in those who have not been previously infected. Public health efforts to control mosquito populations and reduce transmission are crucial in managing and preventing dengue outbreaks.

 

"Dengue Fever- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dengue Fever pipeline landscape is provided which includes the disease overview and Dengue Fever treatment guidelines. The assessment part of the report embraces, in depth Dengue Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dengue Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Dengue Fever R&D. The therapies under development are focused on novel approaches to treat/improve Dengue Fever.

Dengue Fever Emerging Drugs Chapters

This segment of the Dengue Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Dengue Fever Emerging Drugs

• V181: Merck Sharp & Dohme LLC

V181 is an investigational quadrivalent dengue vaccine candidate developed by Merck & Co., aimed at providing immunity against dengue fever, a mosquito-borne viral infection that poses significant health risks worldwide, particularly in tropical and subtropical regions. V181 is based on a purified inactivated virus (PIV) technology. This approach is similar to that used in inactivated vaccines for other viruses, intending to create a strong immune response without causing infection. Early studies suggest that V181 elicits a broad and balanced immune response across all dengue virus types, aiming to provide comprehensive protection and potentially prevent severe outcomes like dengue hemorrhagic fever. Currently the drug is in Phase II stage of its development for the treatment of Dengue. 

 

• EYU-688: Novartis Pharmaceuticals

EYU-688 is a small molecule drug developed by Novartis for the treatment of dengue fever. It targets nonstructural protein 4B (NS4B) and somatostatin receptor (SSTR). The drug is administered orally and currently is in the Phase II stage of development to treat Dengue Fever. 

Further product details are provided in the report……..

 

Dengue Fever: Therapeutic Assessment

This segment of the report provides insights about the different Dengue Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Dengue Fever

There are approx. 8+ key companies which are developing the therapies for Dengue Fever. The companies which have their Dengue Fever drug candidates in the most advanced stage, i.e. Phase II include, Merck Sharp & Dohme LLC and Novartis Pharmaceuticals.

 

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Dengue Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dengue Fever therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dengue Fever drugs.

 

Dengue Fever Report Insights

• Dengue Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Dengue Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dengue Fever drugs?
• How many Dengue Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dengue Fever?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dengue Fever therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Dengue Fever and their status?
• What are the key designations that have been granted to the emerging drugs?